JP6803236B2 - アペリンポリペプチド - Google Patents

アペリンポリペプチド Download PDF

Info

Publication number
JP6803236B2
JP6803236B2 JP2016572433A JP2016572433A JP6803236B2 JP 6803236 B2 JP6803236 B2 JP 6803236B2 JP 2016572433 A JP2016572433 A JP 2016572433A JP 2016572433 A JP2016572433 A JP 2016572433A JP 6803236 B2 JP6803236 B2 JP 6803236B2
Authority
JP
Japan
Prior art keywords
aperin
isolated polypeptide
polypeptide
amino acid
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016572433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526620A5 (https=
JP2017526620A (ja
Inventor
ジェリー ライアン ホルダー，
ジェリー ライアン ホルダー，
ガヤスリ スワミナス，
ガヤスリ スワミナス，
マイケル ジェイ． フローン，
マイケル ジェイ． フローン，
ブライアン アラン ランマン，
ブライアン アラン ランマン，
アントニー ビー． リード，
アントニー ビー． リード，
レスリー ピー． ミランダ，
レスリー ピー． ミランダ，
ジョン ゴードン アレン，
ジョン ゴードン アレン，
アレクサンダー ジェイ． ピックレル，
アレクサンダー ジェイ． ピックレル，
アーロン シー． ジークムント，
アーロン シー． ジークムント，
ルイス ディー． ペニントン，
ルイス ディー． ペニントン，
ブライアント ヤング，
ブライアント ヤング，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2017526620A publication Critical patent/JP2017526620A/ja
Publication of JP2017526620A5 publication Critical patent/JP2017526620A5/ja
Application granted granted Critical
Publication of JP6803236B2 publication Critical patent/JP6803236B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016572433A 2014-06-10 2015-06-10 アペリンポリペプチド Active JP6803236B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010322P 2014-06-10 2014-06-10
US62/010,322 2014-06-10
PCT/US2015/035205 WO2015191781A2 (en) 2014-06-10 2015-06-10 Apelin polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019187458A Division JP2020023539A (ja) 2014-06-10 2019-10-11 アペリンポリペプチド

Publications (3)

Publication Number Publication Date
JP2017526620A JP2017526620A (ja) 2017-09-14
JP2017526620A5 JP2017526620A5 (https=) 2018-07-05
JP6803236B2 true JP6803236B2 (ja) 2020-12-23

Family

ID=54608924

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016572433A Active JP6803236B2 (ja) 2014-06-10 2015-06-10 アペリンポリペプチド
JP2019187458A Pending JP2020023539A (ja) 2014-06-10 2019-10-11 アペリンポリペプチド
JP2021200644A Withdrawn JP2022028961A (ja) 2014-06-10 2021-12-10 アペリンポリペプチド
JP2023210068A Pending JP2024026356A (ja) 2014-06-10 2023-12-13 アペリンポリペプチド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019187458A Pending JP2020023539A (ja) 2014-06-10 2019-10-11 アペリンポリペプチド
JP2021200644A Withdrawn JP2022028961A (ja) 2014-06-10 2021-12-10 アペリンポリペプチド
JP2023210068A Pending JP2024026356A (ja) 2014-06-10 2023-12-13 アペリンポリペプチド

Country Status (8)

Country Link
US (3) US10941182B2 (https=)
EP (3) EP4257152A3 (https=)
JP (4) JP6803236B2 (https=)
AU (1) AU2015274574B2 (https=)
CA (1) CA2951391C (https=)
ES (1) ES2950789T3 (https=)
MX (1) MX370689B (https=)
WO (1) WO2015191781A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170338A (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
EP3649146B1 (en) * 2017-07-03 2024-06-26 The Governors of the University of Alberta Apelin peptides and uses thereof
WO2019023295A1 (en) * 2017-07-27 2019-01-31 Saint Louis University Fatty acid modified human epidermal growth factor
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
WO2019229242A1 (en) * 2018-05-31 2019-12-05 Novo Nordisk A/S Derivatives comprising an apelin analogue and uses thereof
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
EP3887393A1 (en) 2018-11-26 2021-10-06 Novartis AG Lpl-gpihbp1 fusion polypeptides
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
AU2020300527B2 (en) * 2019-07-01 2026-02-05 Valitor, Inc. Hydrophilic linkers for multivalent peptide conjugates
CN114269367A (zh) * 2019-08-15 2022-04-01 科巴公司 治疗性肽
CN110669105B (zh) * 2019-10-31 2021-06-11 华中科技大学 长效多肽构建及其抗急性肾损伤和糖尿病并发肾病的应用
JP7039636B2 (ja) * 2020-02-19 2022-03-22 ソフトバンク株式会社 システム、管理装置、監視端末、及びプログラム
GB202016152D0 (en) * 2020-10-12 2020-11-25 Heptares Therapeutics Ltd Linear Apelin Receptor Agonist
GB202016149D0 (en) * 2020-10-12 2020-11-25 Heptares Therapeutics Ltd Cyclic apelin receptor agonists
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
JP2025001049A (ja) * 2021-09-01 2025-01-08 積水メディカル株式会社 アルギニン誘導体
CN116554267A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 聚乙二醇修饰的激肽或其变体和药物应用
TW202446782A (zh) * 2023-04-11 2024-12-01 美商威特拉公司 愛帕琳受體促效劑及其用途
CN119101143A (zh) * 2023-05-31 2024-12-10 浙江大学 一种G蛋白偏向的apelin-13多肽突变体及应用
WO2025092748A1 (zh) * 2023-11-01 2025-05-08 拜西欧斯（北京）生物技术有限公司 多肽衍生物、其药物组合物及其用途
WO2026007693A1 (zh) * 2024-07-05 2026-01-08 浙江大学 Apelin-13多肽突变体

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4351337A (en) 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US5002936A (en) 1985-04-12 1991-03-26 Seymour Lieberman Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
JPH09509428A (ja) 1994-02-23 1997-09-22 カイロン コーポレイション 薬理学的に活性な薬剤の血清半減期を増加させるための方法および組成物
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
AU5759399A (en) * 1998-09-25 2000-04-17 Takeda Chemical Industries Ltd. Peptide derivative
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DE69911993T2 (de) 1998-12-23 2004-05-19 Amgen Inc., Thousand Oaks Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
JP5013152B2 (ja) 2001-02-28 2012-08-29 株式会社ビーエムジー 蛋白質複合体形成剤
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
ES2561108T3 (es) 2001-10-19 2016-02-24 Idexx Laboratories, Inc. Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
US20070253966A1 (en) 2003-06-12 2007-11-01 Eli Lilly And Company Fusion Proteins
US7323169B2 (en) 2004-04-23 2008-01-29 Amgen Inc. Sustained release formulations
EP2474316B1 (en) 2004-10-07 2016-04-06 The Regents of The University of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
WO2006076736A2 (en) * 2005-01-14 2006-07-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US20060199812A1 (en) 2005-01-24 2006-09-07 Amgen Inc. Method of conjugating aminothiol containing molecules to vehicles
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US20100204113A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of stresscopin-related peptide as a therapeutic agent
EP2408814B1 (en) 2009-03-20 2018-11-21 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
AR084020A1 (es) 2010-11-30 2013-04-17 Genentech Inc Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos
AU2012229336B2 (en) * 2011-03-11 2017-02-02 Genzyme Corporation Pegylated Apelin and uses thereof
EP2785365B1 (en) * 2011-11-28 2017-07-19 Institut National de la Sante et de la Recherche Medicale (INSERM) Pharmaceutical composition for use in the treatment of dysfunction associated with aging
CN104254540A (zh) * 2012-01-09 2014-12-31 安科治疗公司 Apj受体化合物
US8921307B2 (en) * 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
ES2875957T3 (es) * 2012-12-20 2021-11-11 Amgen Inc Agonistas del receptor APJ y usos de los mismos
WO2014152955A1 (en) 2013-03-14 2014-09-25 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof

Also Published As

Publication number Publication date
JP2020023539A (ja) 2020-02-13
EP4257152A2 (en) 2023-10-11
ES2950789T3 (es) 2023-10-13
US20240327461A1 (en) 2024-10-03
JP2024026356A (ja) 2024-02-28
AU2015274574B2 (en) 2019-10-10
CA2951391C (en) 2021-11-02
EP3155002A2 (en) 2017-04-19
WO2015191781A3 (en) 2016-07-21
US20170107255A1 (en) 2017-04-20
EP3674314A3 (en) 2020-07-29
EP3674314B8 (en) 2023-07-12
MX2016016337A (es) 2017-09-01
US10941182B2 (en) 2021-03-09
US20210261619A1 (en) 2021-08-26
EP3674314B1 (en) 2023-05-03
WO2015191781A2 (en) 2015-12-17
CA2951391A1 (en) 2015-12-17
EP4257152A3 (en) 2023-12-06
AU2015274574A1 (en) 2016-12-22
MX370689B (es) 2019-12-19
US11807693B2 (en) 2023-11-07
EP3674314A2 (en) 2020-07-01
EP3155002B1 (en) 2019-11-27
JP2022028961A (ja) 2022-02-16
JP2017526620A (ja) 2017-09-14

Similar Documents

Publication Publication Date Title
JP6803236B2 (ja) アペリンポリペプチド
JP6710253B2 (ja) Ａｐｊ受容体アゴニストおよびその使用
CN102625811B (zh) Fgf21突变体及其用途
US8748571B2 (en) Thrombopoietic compounds
KR100679576B1 (ko) 수용체에 결합하는 펩티드 및 화합물
ES2395413T3 (es) Péptidos que se unen al receptor de eritropoyetina
CN106163569B (zh) 活化的神经降压素分子及其用途
WO2024212817A1 (zh) 一种氯毒素类似物的多肽偶联物及其用途
KR101775625B1 (ko) 혈장 내에서 안정성이 증가된 신규한 세포투과성 펩타이드 및 이것의 용도
WO2024199481A1 (zh) 蛋白类似物及其应用
WO2025206033A1 (ja) ｕＰＡＲ結合性ＨＬＨペプチド、ペプチド－薬物複合体および組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191011

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200706

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200706

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200720

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201130

R150 Certificate of patent or registration of utility model

Ref document number: 6803236

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250